Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Immutep LimitedNASDAQ: IMMP

Selling, General & Admin · Q2 FY2026 · quarter ended Dec 2025

Selling, general & admin grows 28.2% year over year

Q2 FY2026 selling, general & admin of A$5.43M rose 28.2% year over year. Over 3 fiscal years it compounded at +6.2% a year.

Context

  • Selling, general & admin amounted to 171.4% of revenue in FY2025, down 59.0 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of A$170.66M (+1874.3%) for the fiscal year ending Jun 2026, a step up from the -2.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
A$5.43M— QoQ
Last fiscal yearJun 2025
A$8.64M-2.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.2%——
1 year-2.4%+1874.3%+1876.6 pp
3-year CAGR+6.2%+8.7%+2.4 pp
5-year CAGR+278.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

AUD · from the income statement

Latest · FY2025
8.64M AUD
Year-over-year change
-2.4%
4-year CAGR
+8.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.4% is the 7th highest of 11, against a peer median of +5.3%.
  • Selling, general & admin amounts to 171.4% of revenue for IMMP, versus a peer median of 120.9%.
IMMP Competitors
Selling, General & Admin for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$256.23M USD+54.0%+20.4%117.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M USD-11.2%-10.5%—
EDITEditas Medicine, Inc.LTM Mar 2026$46.76M USD-29.2%-11.0%120.9%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.9M USD+4.0%+10.2%712.8%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$33.2M USD+76.0%+43.8%—
CABACabaletta Bio, Inc.LTM Mar 2026$28.39M USD-5.3%+25.8%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$26.76M USD+58.7%+29.7%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$20.1M USD+39.9%+8.1%—
MREOMereo BioPharma Group plcLTM Mar 2026$19.76M USD-28.1%-0.2%3951.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€14.33M EUR+6.6%-8.9%106.6%
IMMPImmutep LimitedFY2025A$8.64M AUD-2.4%+6.2%171.4%
Peer median (excluding IMMP) —+5.3%+9.2%120.9%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue3.86M170.37K3.51M3.84M5.04M
Cost of Revenue17.24M2.06M2.06M41.55M61.41M
Gross Profit(13.37M)(1.89M)1.44M(37.7M)(56.37M)
Gross Margin-346.2%-1111.2%41.2%-981.4%-1117.6%
Research & Development17.24M31.34M28.79M41.55M61.41M
Selling, General & Admin6.28M7.21M14.08M8.85M8.64M
Operating Expenses18.3M32.55M44.94M50.4M70.06M
Depreciation & Amortization1.89M1.84M1.86M2.01M2.13M
EBITDA(17.77M)(31.87M)(39.57M)(44.54M)(62.88M)
EBITDA Margin-460.0%-18708.9%-1128.8%-1159.4%-1246.6%
Operating Income(31.68M)(33.94M)(77.69M)(88.1M)(126.42M)
Operating Margin-820.0%-19920.0%-2216.0%-2293.3%-2506.5%
Interest Income105.33K224.52K939K3.88M5.25M
Interest Expense9.83K92.43K20.4K30.59K24.01K
Other Income / Expenses1.77M1.63M37.79M45.39M64.99M
Income Before Tax(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Pre-Tax Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
Income Tax Expense3334000
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Net Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
EPS (Basic)(0.49)(0.37)(0.44)(0.36)(0.42)
EPS (Diluted)(0.49)(0.37)(0.44)(0.36)(0.42)
Weighted Avg Shares60.43M86.23M90.06M119.99M145.58M
Weighted Avg Shares (Diluted)60.43M86.23M90.06M120.11M145.58M

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.